30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q Revenue: Zimmer

$1,106MM, +3% (Americas $638MM, +1%; Europe $271MM, +6%; Asia Pacific $197MM, +7%)

Reconstructive $824MM, +5% (Americas $469MM, +3%; Europe $210MM, +6%; Asia Pacific $145MM, +7%)

  • Hips $316MM, +3% (Americas $150MM, flat; Europe $100MM, +3%; Asia Pacific $66MM, +10%)
  • Knees $461MM, +6% (Americas $285MM, +6%; Europe $101MM, +10%; Asia Pacific $75MM, +4%)
  • Extremities $47MM, +2%
  • Dental $54MM, -2%

Trauma $78MM, -1% (Americas -6%, Europe -1%, Asia Pacific +9%)

Spine $51MM, +6%

Surgical/Other $99MM, -4%


  • Acquired ETEX, bone substitute materials provider
  • Pricing update: -2.2% overall, sequential improvement attributed to increased global penetration with new products, positive long term clinical validations of legacy products in key ex-U.S. markets, etc.; hips positive volume/mix 5.2%, price -2.5%; knees positive volume/mix of 9.2% with price -2.9%
  • Global hip sales led by Continuum Acetabular system, BIOLOX delta ceramic heads, etc.
  • Vivacit-C poly liners now evaluated for >90MM cycles of wear testing
  • 10 hip brands achieved Class A 10-year rating by U.K.’s Orthopaedic Data Evaluation Panel
  • Surpassed 100,000 implantations of Persona knee since launch
  • Competitive shoulders still presenting headwinds in U.S., but double-digit growth in EMEA and Asia Pacific
  • Launched Distal Radius Plating System in certain European markets